Prunus africana (Hook.f.) Kalkman (syn. Pygeum africanum) · herb
Evidence tier: weak
Reduces symptoms of benign prostate enlargement, improves urinary flow, reduces night time urination, and supports prostate comfort
Bark extract of the African cherry. MSK identifies several laboratory pathways: it blocks the production of inflammatory 5 lipoxygenase metabolites, it contains compounds (atraric acid and N butylbenzenesulfonamide) that act as androgen receptor antagonists, and it suppresses prostate cell growth signalling including transforming growth factor beta 1. Plausible and multiple, but all laboratory pathways, none demonstrated to be the operating mechanism in men.
Weak, and the number the seed quotes is real but is being read far too generously. There IS a Cochrane review (Wilt, Ishani, MacDonald, Rutks, Stark; CD001044, 2002) pooling 18 trials in 1,562 men with benign prostatic hyperplasia, and it did report that men taking Pygeum africanum were about twice as likely to report improvement in urinary symptoms as men on placebo, with nocturia down about 19 percent and peak urine flow up about 23 percent. Four things gut that headline. First, Cochrane's own quality verdict: the studies were SMALL, of SHORT duration, used varied doses and preparations, and RARELY reported outcomes using standardised validated efficacy measures. Second, the review is from 2002 and has not been refreshed; the field simply moved on and left pygeum unstudied. Third, MSK's current position is preliminary, not supportive: several clinical trials show pygeum is effective for urinary symptoms in BPH, but long term effectiveness and safety are NOT KNOWN, and larger studies are needed to compare it with standard treatments. Fourth, and most damning, look at what happened to the better studied herb in the same category. Saw palmetto had far more trials than pygeum, and when it was finally tested properly in two large, rigorous, independently funded, adequately powered trials, STEP and CAMUS, it was FLAT NEGATIVE, no better than placebo, even at triple dose. The lesson generalises: a pile of small, poorly measured, positive BPH herb trials is exactly the signature that the two definitive trials in this field demolished. Pygeum has never had its STEP or CAMUS moment. Until it does, the honest read is that its evidence sits in precisely the state saw palmetto's did before the truth came out.
The sources do not establish a defensible standard dose. Cochrane specifically records that the included trials used VARIED DOSES AND PREPARATIONS, which is one of the reasons it declined to give firm guidance, and MSK notes that any effect takes several weeks to appear. Any single milligram figure circulating for pygeum is a product convention rather than a sourced efficacy dose.
Take 100 to 200mg of standardised bark extract daily with food. Allow 6 to 8 weeks to assess urinary and prostate symptom improvement.
Generally well tolerated. Mild GI side effects possible. P. africanum is a protected and vulnerable species due to overharvesting, ensure sustainably or organically sourced product. Avoid with anticoagulants.
Pregnancy: unknown
Breastfeeding: unknown
Active compounds: phytosterols (beta sitosterol), pentacyclic triterpenes (ursolic acid, oleanolic acid), ferulic acid esters, atraric acid, N butylbenzenesulfonamide
Remedies using Pygeum · Browse by body system · Check it against what you take
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.